|1.||Kaku, Taiichi: 8 articles (01/2015 - 07/2008)|
|2.||Liu, Qi: 7 articles (09/2013 - 07/2008)|
|3.||Wang, Changyuan: 7 articles (09/2013 - 07/2008)|
|4.||Liu, Kexin: 7 articles (09/2013 - 07/2008)|
|5.||Ma, Xiaochi: 5 articles (09/2013 - 06/2009)|
|6.||Peng, Jinyong: 5 articles (09/2013 - 07/2008)|
|7.||Sun, Huijun: 5 articles (09/2013 - 07/2008)|
|8.||Meng, Qiang: 5 articles (09/2013 - 04/2011)|
|9.||Guo, Xinjin: 3 articles (09/2013 - 07/2012)|
|10.||Liu, Tao: 2 articles (11/2012 - 07/2012)|
|1.||Acute Kidney Injury (Acute Renal Failure)
09/01/2013 - "These results indicated that JBP485 improved acute renal failure by increasing the expression and function of Oat1 and Oat3, and by decreasing overoxidation of the kidney in gentamicin-induced ARF rats. "
11/01/2012 - "The purpose of this study is to investigate whether the effect of cyclo-trans-4-l-hydroxyprolyl-l-serine (JBP485) on acute renal failure (ARF) induced by cisplatin is related to change in expression of renal Oat1, Oat3 and Mrp2 in rats. "
09/01/2013 - "JBP485 improves gentamicin-induced acute renal failure by regulating the expression and function of Oat1 and Oat3 in rats."
11/01/2012 - "Changes in expression of renal Oat1, Oat3 and Mrp2 in cisplatin-induced acute renal failure after treatment of JBP485 in rats."
04/01/2011 - "Cyclo-trans-4-L-hydroxyprolyl-L-serine (JBP485) is a dipeptide with anti-hepatitis activity that has been chemically synthesized. "
06/01/2009 - "We thought it valuable to clarify the anti-hepatitis molecular mechanism of JBP485 to develop a new oral anti-hepatitis drug. "
07/28/2008 - "Evidence has indicated that JBP485 exhibits potent anti-hepatitis activity. "
03/12/2013 - "Entecavir and JBP485 (a dipeptide) exhibit the antihepatitis activities and it is possible for the two drugs to be coadministered in the treatment of hepatitis. "
|4.||Obstructive Jaundice (Cholestatic Jaundice)
|3.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)